NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kling Biotherapeutics

Kling Biotherapeutics

Private
AmsterdamHealthcare & Life Scienceshttps://www.klingbio.com/

Last Round

Seed

Jan 1, 2021

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Kling Biotherapeutics is a biotechnology company that discovers and develops antibody-based therapeutics for cancer and infectious diseases using its proprietary B-cell immortalization technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

antibody discoveryb-cell immortalizationbiotechtherapeutic antibodiesdrug discovery platformaffinity maturationclinical-stage biotechhuman antibodiesbiopharmadrug pipelineantibody engineeringr&d partnershiptherapeutic targets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kling Biotherapeutics Comparables

Compare Kling Biotherapeutics with similar companies based on industry and business-model similarity.

Kling Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HiFiBiO
82%
Vir Biotechnology
73%
Immunome, Inc.
73%

Kling Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 1, 2021

Kling Biotherapeutics Investors

Notable investors and investment history

Kling Biotherapeutics investors
InvestorRounds
Time BioVenturesSeed
UvA Ventures Holding BVSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors grew 109% MoM, reaching 1.8K.

  • Jan 21, 2026

    Monthly visitors increased 41% MoM, reaching 2.2K.

Kling Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kling Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kling Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAmsterdam
Employee Range11
Year Founded2021
Last FundingJan 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.